Investing
Nucryst Pharmaceuticals (NCST) Rallies Like A House On Fire
Published:
Nucryst Pharmaceuticals (NCST) is up over 100% to $4.40 on news that the FDZ cleared its antimicrobial cream containing the compound NPI 32101 Of course, there was no revenue forecast attached to the news.
Nucryst investors have had a frightening ride over the last year. Shares were at $16 a year ago. They were below $2 in early July.
The stock is another example of the craziness attached to micro-cap pharma stocks. In the last quarter, the company lost almost $2 million on just over $5 million in revenue. Today it has an $80 million market cap.
Douglas A. McIntyre
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the
advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.